By antagonizing SKP2‐mediated C‐MYC ubiquitination (Figure 5), PDCD11 disrupts the balance between C‐MYC and SKP2, resulting in uncontrolled C‐MYC signaling and tumor progression (Figure 7A). Here, PDCD11 is linked to neoplasm.